What’s New in Research for Blood Cancer Treatments?

The past two years have seen a surge of new treatments for blood cancers, such as lymphoma, leukemia and multiple myeloma. Research on the genetic flaws underlying specific cancer types has led to new precision drugs such as ibrutinib and idelalisib and new immunotherapy agents that are improving outcomes in many patients with difficult-to-treat forms of blood cancers.

Just in the last year, four new therapies have been approved for patients with chronic lymphocytic leukemia (CLL), the most common adult leukemia. An estimated 15,700 people in the U.S. were diagnosed with CLL last year, most of them elderly – the average age at diagnosis is 70. The transformation of CLL treatment was named the cancer Advance of the Year by the American Society of Clinical Oncology (ASCO).

blood cancers, myeloma, laboratoryTwo of the drugs – ibrutinib and idelalisib – work so well in older patients whose cancer has recurred or become resistant that specialists say they could eventually eliminate the need for traditional chemotherapy in these patients. The other two drugs – obinutuzumab and ofatumumab – have shown to slow disease progression in newly diagnosed CLL by about a year.

In a clinical trial co-led by a Dana-Farber researcher, a new oral targeted drug has shown encouraging anti-cancer activity in patients with resistant or relapsed acute myeloid leukemia (AML). The drug, known as ABT-199 or venetoclax, blocks the cancer cells’ mechanisms that allow them to survive despite being ordered to self-destruct, says Anthony Letai, MD, PhD, senior author of the report earlier this year. In another clinical trial, venetoclax improved outcomes in patients with a hard-to-treat form of CLL, and is expected to gain FDA approval for this indication next year.

New immunotherapy drugs that have shown dramatic results in melanoma may also prove to be treatment options for blood cancers. Researchers reported last December that the immunotherapy agent nivolumab achieved complete or partial remission in 87 percent of patients with resistant forms of Hodgkin lymphoma, many of whom had stem cell transplants and treatment with several drugs. The majority of patients in the small trial who responded to the drug were still doing well a year after treatment – a very encouraging result.

Another treatment strategy that combines immunotherapy and gene therapy shows promise in non–Hodgkin lymphoma (NHL). The strategy uses CAR T- cells, which are T cells engineered with synthetic receptors that can target surface molecules on cancer cells. By doing so, they can selectively find the tumor cells and destroy them, while leaving healthy cells intact. They have achieved some dramatic responses and remissions in blood cancers, mainly B cell malignancies or AML. Recently, CAR T- cell treatment was tried in four patients with advanced multiple myeloma, achieving two complete responses.

At least five new agents are either approved or expected to be approved for treating multiple myeloma this year.

Panobinostat combined with bortezomib and dexamethasone – a concept discovered at Dana-Farber and developed through Dana-Farber-led clinical trials, was approved for relapsed and refractory myeloma.

A breakthrough antibody immunotherapy called daratumumab, developed in a Dana-Farber partnership with European researchers, produced partial or complete remissions in at least one-third of myeloma patients who had exhausted many previous treatments. Larger trials of the compound are under way.

Another immunotherapy drug, elotuzumab, proved effective in a phase 3 trial of patients with drug-resistant or relapsed multiple myeloma. Given in combination with lenalidomide and dexamethasone, elotuzumab prolonged by 30 percent the average time before the disease began to worsen.

Finally, ixazomib – the first oral proteasome inhibitor to enter phase three trials – is expected to be approved by the end of the year.

Comments Sort By Newest

2 thoughts on “What’s New in Research for Blood Cancer Treatments?

  1. I saw a documentary in which a measles virus mutation was being used as a protocol for multiple myeloma. Is this a promising treatement?

    • Dear Anna —
      Thank you for your question and for reading Insight. Some research attracting journalistic attention is a clinical trial at the Mayo Clinic that uses the measles virus to treat patients with multiple myeloma. Investigators found that after infecting cancer cells, the virus causes them to clump together and disintegrate. The wreckage may trigger an immune system response that can prevent the disease from returning for a long period of time, researchers have suggested. Research is ongoing, and we will be sure to update our blog when/if we hear more.

  2. I saw a documentary in which a measles virus mutation was being used as a protocol for multiple myeloma. Is this a promising treatement?

    1. Dear Anna —
      Thank you for your question and for reading Insight. Some research attracting journalistic attention is a clinical trial at the Mayo Clinic that uses the measles virus to treat patients with multiple myeloma. Investigators found that after infecting cancer cells, the virus causes them to clump together and disintegrate. The wreckage may trigger an immune system response that can prevent the disease from returning for a long period of time, researchers have suggested. Research is ongoing, and we will be sure to update our blog when/if we hear more.

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.